查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595441

多囊性卵巢治疗市场：按药物类别、手术、分销管道划分 - 全球预测 2025-2030

Polycystic Ovarian Syndrome Treatment Market by Drug Class (Anti-Depressants, Anti-Obesity, Insulin Sensitizing Agents), Surgery (Laparoscopic Ovarian Drilling, Ovarian Wedge Resection), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年多卵巢症候群治疗市场价值为32.5亿美元，预计2024年将达到34.5亿美元，复合年增长率为6.63%，到2030年将达到50.9亿美元，预计将达到1000万美元。

卵巢症候群 (PCOS) 治疗市场包括药品、营养食品和旨在控制月经、不孕和代谢问题等症状的生活方式干预措施。 PCOS 的高盛行率推动了这一市场的需求，影响着全球约 5-10% 的育龄妇女，影响着身心健康。用途范围从荷尔蒙避孕药和Metformin等胰岛素增敏药物到旨在缓解症状和促进生育能力的手术选择。最终用途主要是医院、生育诊所和使用非处方补充品和同类疗法疗法的个人。

主要市场统计
基准年[2023] 32.5亿美元
预测年份 [2024] 34.5亿美元
预测年份 [2030] 50.9亿美元
复合年增长率（%） 6.63%

影响市场成长的主要因素包括由于诊断方法的改进和医疗保健资讯的可用性的增加而提高了对 PCOS 的认识。此外，个人化医疗的创新和新治疗策略的引入为製药公司解决症状管理中未满足的需求提供了潜在的机会。然而，荷尔蒙疗法的副作用、缺乏明确的治疗方法、高昂的治疗费用以及某些地区的社会文化障碍等限制因素给市场扩张带来了挑战。

创新领域包括天然和生物同质荷尔蒙疗法荷尔蒙疗法的开发、促排卵药物的进步以及体重管理方法的改进。他们也有潜力利用远端医疗和健康应用程式等数位健康解决方案来提高患者的参与度和合规性。该市场的特点是整体治疗方法的新兴趋势，将现代医学与生活方式调整和替代疗法相结合。公司可以透过投资多囊性卵巢症候群遗传和代谢原因的研究，利用日益增长的消费者对个人化医疗保健解决方案的趋势。透过开展宣传活动和教育计划来提高意识，同时确保可负担性和可及性，公司可以接触更多消费者并帮助企业在竞争中成长，不断发展的医疗保健政策可以为企业提供强有力的手段。

市场动态：快速发展的多囊性卵巢症候群治疗市场的关键市场洞察

多囊性卵巢症候群治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球多囊性卵巢症候群盛行率不断上升
    • 组合药物的采用增加
    • 加大组织力度，意识提升
  • 市场限制因素
    • 核准的多囊性卵巢症候群治疗药物
  • 市场机会
    • 正在进行的药物开发研究和开发计划
    • 策略联盟和投资以扩大产能
  • 市场挑战
    • PCOS治疗药物与治疗副作用

波特五力：驾驭多囊性卵巢治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解多囊性卵巢卵巢治疗市场的外部影响

外部宏观环境因素在塑造多囊性卵巢症候群治疗市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解多囊性卵巢治疗市场的竞争格局

卵巢症候群治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵多囊性卵巢症候群治疗市场供应商的绩效评估

FPNV 定位矩阵是评估多囊性卵巢症候群治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘卵巢症候群治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对卵巢症候群治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 多囊性卵巢症候群（PCOS）盛行率在全球增加
      • 联合用药的采用率增加
      • 加大组织力度，提高人们对 PCOS 的认识
    • 抑制因素
      • 缺乏核准治疗多囊性卵巢症候群的药物
    • 机会
      • 正在进行的药物开发研究和开发计划
      • 策略联盟投资与产能扩张
    • 任务
      • 多囊性卵巢症候群药物和治疗的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的卵巢症候群治疗市场

  • 抗忧郁症
  • 预防肥胖
  • 胰岛素增敏剂
  • 口服避孕药

第七章卵巢手术治疗市场

  • 腹腔镜卵巢穿孔
  • 卵巢楔形切除术

第八章多囊性卵巢治疗市场：依分销管道

  • 药局
  • 电子商务
  • 不孕不育治疗诊所
  • 医院药房

第九章北美和南美卵巢症候群治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太多囊卵巢卵巢治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲卵巢症候群治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Ferring BV
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-957C47F91255

The Polycystic Ovarian Syndrome Treatment Market was valued at USD 3.25 billion in 2023, expected to reach USD 3.45 billion in 2024, and is projected to grow at a CAGR of 6.63%, to USD 5.09 billion by 2030.

The Polycystic Ovarian Syndrome (PCOS) treatment market encompasses a range of pharmaceuticals, nutraceuticals, and lifestyle interventions aimed at managing symptoms like menstrual irregularities, infertility, and metabolic issues. This market's necessity stems from the high prevalence of PCOS, affecting approximately 5-10% of women of reproductive age globally, with implications for both physical and mental health. Applications extend from hormonal birth control and insulin-sensitizing agents like metformin to surgical options, intended to alleviate symptoms and promote fertility. End-use primarily revolves around hospitals, fertility clinics, and individuals utilizing over-the-counter supplements and homeopathic remedies.

KEY MARKET STATISTICS
Base Year [2023] USD 3.25 billion
Estimated Year [2024] USD 3.45 billion
Forecast Year [2030] USD 5.09 billion
CAGR (%) 6.63%

Key factors influencing market growth include increasing awareness of PCOS among demographics due to enhanced diagnostic procedures and accessible healthcare information. Additionally, innovation in personalized medicine and the introduction of new treatment strategies present potential opportunities for pharmaceutical companies to address the unmet needs in symptom management. However, limitations like side effects of hormonal treatments, lack of definitive cures, high treatment costs, and socio-cultural obstacles in certain regions pose challenges to market expansion.

Areas ripe for innovation include the development of natural and bio-identical hormone therapies, advancements in ovulation-induction medications, and improved methods for weight management. There's also potential in leveraging digital health solutions, such as telemedicine and health apps, for enhanced patient engagement and compliance. The market is characterized by emerging trends in holistic treatment approaches, integrating modern medicine with lifestyle adjustments and alternative therapies. Businesses can capitalize on the growing consumer inclination towards personalized healthcare solutions by investing in research focused on genetic and metabolic drivers of PCOS. Ensuring affordability and accessibility, while creating awareness through campaigns and educational programs, can enable companies to capture a broader audience, offering robust avenues for business growth amid competition and evolving healthcare policies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Polycystic Ovarian Syndrome Treatment Market

The Polycystic Ovarian Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of PCOS worldwide
    • Increasing adoption of combination drugs
    • Rising organizational efforts to create awareness regarding PCOS
  • Market Restraints
    • Lack of approved drugs for PCOS
  • Market Opportunities
    • Ongoing research and development projects for drug development
    • Strategic alliances and investment for capacity expansion
  • Market Challenges
    • Side effects of PCOS drugs and treatment

Porter's Five Forces: A Strategic Tool for Navigating the Polycystic Ovarian Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Polycystic Ovarian Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Polycystic Ovarian Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Polycystic Ovarian Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Polycystic Ovarian Syndrome Treatment Market

A detailed market share analysis in the Polycystic Ovarian Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Polycystic Ovarian Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Polycystic Ovarian Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Polycystic Ovarian Syndrome Treatment Market

A strategic analysis of the Polycystic Ovarian Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Polycystic Ovarian Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Ferring B.V., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Polycystic Ovarian Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-Depressants, Anti-Obesity, Insulin Sensitizing Agents, and Oral Contraceptives.
  • Based on Surgery, market is studied across Laparoscopic Ovarian Drilling and Ovarian Wedge Resection.
  • Based on Distribution Channel, market is studied across Drug Stores, E-Commerce, Fertility Clinics, and Hospital Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of PCOS worldwide
      • 5.1.1.2. Increasing adoption of combination drugs
      • 5.1.1.3. Rising organizational efforts to create awareness regarding PCOS
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of approved drugs for PCOS
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development projects for drug development
      • 5.1.3.2. Strategic alliances and investment for capacity expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of PCOS drugs and treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Polycystic Ovarian Syndrome Treatment Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Depressants
  • 6.3. Anti-Obesity
  • 6.4. Insulin Sensitizing Agents
  • 6.5. Oral Contraceptives

7. Polycystic Ovarian Syndrome Treatment Market, by Surgery

  • 7.1. Introduction
  • 7.2. Laparoscopic Ovarian Drilling
  • 7.3. Ovarian Wedge Resection

8. Polycystic Ovarian Syndrome Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. E-Commerce
  • 8.4. Fertility Clinics
  • 8.5. Hospital Pharmacies

9. Americas Polycystic Ovarian Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Polycystic Ovarian Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Eli Lilly and Company
  • 6. Ferring B.V.
  • 7. Johnson & Johnson Services, Inc.
  • 8. Lupin Limited
  • 9. Merck & Co., Inc.
  • 10. Mylan N.V.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN SENSITIZING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY LAPAROSCOPIC OVARIAN DRILLING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY OVARIAN WEDGE RESECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023